OncoSec Medical (NASDAQ: ONCS) and Intrexon Corporation (NYSE:XON) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

9.0% of OncoSec Medical shares are held by institutional investors. Comparatively, 82.1% of Intrexon Corporation shares are held by institutional investors. 11.5% of OncoSec Medical shares are held by company insiders. Comparatively, 55.1% of Intrexon Corporation shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

OncoSec Medical has a beta of 2.53, indicating that its share price is 153% more volatile than the S&P 500. Comparatively, Intrexon Corporation has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.

Valuation & Earnings

This table compares OncoSec Medical and Intrexon Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
OncoSec Medical N/A N/A -$21.73 million ($1.06) -1.08
Intrexon Corporation $202.92 million 9.68 -$99.62 million ($1.03) -15.83

OncoSec Medical has higher revenue, but lower earnings than Intrexon Corporation. Intrexon Corporation is trading at a lower price-to-earnings ratio than OncoSec Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares OncoSec Medical and Intrexon Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OncoSec Medical N/A -108.04% -88.54%
Intrexon Corporation -60.63% -19.08% -11.53%

Analyst Ratings

This is a breakdown of current recommendations for OncoSec Medical and Intrexon Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OncoSec Medical 0 0 5 0 3.00
Intrexon Corporation 0 1 5 0 2.83

OncoSec Medical presently has a consensus target price of $5.33, indicating a potential upside of 367.84%. Intrexon Corporation has a consensus target price of $43.20, indicating a potential upside of 165.03%. Given OncoSec Medical’s stronger consensus rating and higher probable upside, analysts plainly believe OncoSec Medical is more favorable than Intrexon Corporation.

Summary

Intrexon Corporation beats OncoSec Medical on 6 of the 11 factors compared between the two stocks.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.